Grants Awarded: 

To date, in under three years of existence, Cash Memorial has been responsible for over $300,000 in grants to the cancer research community!  Here's where it all went:


2009:

A grant was awarded to Dr. Carl Novina, Associate Professor of Microbiology & Immunobiology, Harvard Medical School and Dana-Farber Cancer Institute. 

Dr. Novina work involves an exciting genetic research project which may change the course of cancer research and treatment options.  He and his colleagues have discovered a way to perform “gene silencing”.  By “turning off” a specific gene, he is able to determine not only what that gene does, but also whether it could be a trigger to the organization of cancer cells with our bodies.  His research has broad reaching potential and has already assisted other researchers in many different genres.

2010:

A grant was awarded to Dr. Carl Novina to continue his worthy research in genetic silencing techniques.  This grant was matched by a generous Trustee of the Dana Farber Cancer Institute, and these funds were awarded to the general research funds at the institute to benefit all doctors in their research endeavors, thereby doubling our effective donation!

A grant was awarded to Dr. Patrick Wen,
Professor, Department of Neurology at the Harvard Medical School and
Director of Neuro-oncology at Brigham And Women's Hospital. 

Dr. Wen's work involves research on the PI3 kinase pathway inhibitors.  Alterations to this pathway are near-universal in this disease and are essential for glioblastoma tumor growth.  Multiple drugs targeting PI3 kinase are either in or entering clinical trials.  However, the concern exists that resistance mechanisms may arise against single agents targeting this pathway.  The use of combination therapies with two or more agents targeting this or related pathways may overcome resistance, enabling more effective killing of tumor cells.  Dr. Wen is exploring these alternatives with the help of this recent grant.

2011, 2012 and 2013: 

Grants were awarded each year to Dr. Carl Novina to continue his work in gene silencing techniques.  The grants provided to Dr. Novina have funded the research necessary for a very important study that has recently been concluded and published.  Stop back for a link to this important paper. This grant was matched by a generous Trustee of the Dana Farber Cancer Institute, and these funds were awarded to the general research funds at the institute to benefit all doctors in their research endeavors, thereby doubling our effective donation!

Grants were awarded each year to Matthew Meyerson, MD, PhD and William Hahn, MD, PhD and the Center for Cancer Genome Discovery.  Drs. Myerson and Hahn's research involves an expansion of the use of the OncoMap —a genome-probing technology that Dr. Meyerson and his colleagues designed to detect hundreds of genetic abnormalities that are known to fuel malignant growth in many different types of cancer. The OncoMap focuses on mutations that represent particularly good targets for therapeutic intervention. The detection method is remarkably rapid, allowing researchers to look for all of these mutations at one time. Scientists have used the technology on a broad array of tumor tissues to learn which mutations contribute to particular types of cancer.  Dana-Farber plans to use this OncoMap on a much broader population to learn how mutations influence the responses of individual tumors to specific cancer treatments. The project will give each patient who comes to the Institute and its partner hospitals the opportunity to submit tumor samples for genomic analysis. Using OncoMap, technicians will analyze each tissue sample in search of cancer-promoting mutations. Researchers will link OncoMap results to clinical histories, including information about which drugs are used to treat each patient and how the patient ultimately fares. The data may help us learn why a given drug is effective in some patients but not others, paving the way for more personalized treatment strategies.  This grant was matched by a generous Trustee of the Dana Farber Cancer Institute, and these funds were awarded to the general research funds at the institute to benefit all doctors in their research endeavors, thereby doubling our effective donation!
  

Grants were awarded each year to Dr. Patrick Wen, Professor, Department of Neurology at the Harvard Medical School and Director of Neuro-oncology at Brigham And Women's Hospital to continue his research on the PI3 kinase pathway inhibitors.   This grant was matched by a generous Trustee of the Dana Farber Cancer Institute, and these funds were awarded to the general research funds at the institute to benefit all doctors in their research endeavors, thereby doubling our effective donation!


2014 and 2015:


Grants were awarded to Dr. Novina and Dr. Wen for their continued research in their respective fields in gene silencing techniques and kinetic pathway prohibitors.  Congratulations for your fine work gentlemen!





 
 
  Site Map